{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:13:37Z","timestamp":1778033617864,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04817-5","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:34:38Z","timestamp":1774596878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alignment of 5\u20132\u20131 criteria with Neurologists' clinical judgment in identifying Advanced Parkinson\u2019s Disease in Morocco: A cross-sectional inter-rater agreement study"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohamed","family":"Daghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zineb","family":"Serhier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelhakim","family":"Lakhdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hicham","family":"El Otmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"4817_CR1","doi-asserted-by":"crossref","unstructured":"Aslam S, Manfredsson F, Stokes A, Shill H. Advanced Parkinson\u2019s disease: A review. Parkinsonism Relat Disord. June 2024;123:106065.","DOI":"10.1016\/j.parkreldis.2024.106065"},{"issue":"12","key":"4817_CR2","first-page":"1529","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced Parkinson\u2019s or complex phase Parkinson\u2019s disease? Re-evaluation is needed. J Neural Transm Vienna Austria 1996. 2017;124(12):1529\u201337.","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"4817_CR3","first-page":"4047392","volume":"2017","author":"MR Luquin","year":"2017","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson\u2019s Disease: A Neurologists-Based Delphi Study (CEPA Study). Park Dis. 2017;2017:4047392.","journal-title":"Park Dis"},{"key":"4817_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, et al. Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord. 2021;92:59\u201366.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"4817_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00415-009-0069-1","volume":"256","author":"E Moro","year":"2009","unstructured":"Moro E, Allert N, Eleopra R, Houeto JL, Phan TM, Stoevelaar H, et al. A decision tool to support appropriate referral for deep brain stimulation in Parkinson\u2019s disease. J Neurol. 2009;256(1):83\u20138.","journal-title":"J Neurol"},{"key":"4817_CR6","doi-asserted-by":"crossref","unstructured":"Okun MS, Fernandez HH, Pedraza O, Misra M, Lyons KE, Pahwa R et al. Development and initial validation of a screening tool for Parkinson disease surgical candidates. Neurol July 13 2004;63(1):161\u20133.","DOI":"10.1212\/01.WNL.0000133122.14824.25"},{"issue":"12","key":"4817_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin"},{"key":"4817_CR8","first-page":"7537924","volume":"2020","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus Fonticoba T, Su\u00e1rez Castro E, Aneiros D\u00edaz A, McAfee D. 5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson\u2019s Treatment. Park Dis. 2020;2020:7537924.","journal-title":"Park Dis"},{"issue":"6","key":"4817_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/nmt-2023-0025","volume":"13","author":"H El Otmani","year":"2023","unstructured":"El Otmani H, Daghi M, Tahiri Jouti N, Lesage S. An overview of the worldwide distribution of LRRK2 mutations in Parkinson\u2019s disease. Neurodegener Dis Manag. 2023;13(6):335\u201350.","journal-title":"Neurodegener Dis Manag"},{"key":"4817_CR10","doi-asserted-by":"publisher","first-page":"108113","DOI":"10.1016\/j.clineuro.2023.108113","volume":"236","author":"M Daghi","year":"2024","unstructured":"Daghi M, Lakhdar A, El Otmani H. Deep brain stimulation for movement disorders treatment in Africa: The current status, outcomes, and challenges. Clin Neurol Neurosurg. 2024;236:108113.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"4817_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.","journal-title":"BMC Neurol"},{"issue":"1","key":"4817_CR12","first-page":"1","volume":"98","author":"Z Serhier","year":"2020","unstructured":"Serhier Z, Bendahhou K, Ben Abdelaziz A, Bennani MO. Methodological sheet n\u00b01: How to calculate the size of a sample for an observational study? Tunis Med. 2020;98(1):1\u20137.","journal-title":"Tunis Med"},{"issue":"12","key":"4817_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"4817_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"3","key":"4817_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276\u201382.","journal-title":"Biochem Med"},{"issue":"2\u20133","key":"4817_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17582024.2025.2481818","volume":"15","author":"M Daghi","year":"2025","unstructured":"Daghi M, Serhier Z, Lakhdar A, El Otmani H. Advanced Parkinson\u2019s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study. Neurodegener Dis Manag. 2025;15(2\u20133):65\u201376.","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"4817_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75(1):9\u201310.","journal-title":"JAMA Neurol"},{"issue":"5","key":"4817_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/nmt-2020-0021","volume":"10","author":"J Aldred","year":"2020","unstructured":"Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, et al. Application of the 5-2-1 screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag. 2020;10(5):309\u201323.","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"4817_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","volume":"22","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022;22(1):35.","journal-title":"BMC Neurol"},{"issue":"1","key":"4817_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42466-022-00176-x","volume":"4","author":"DJ Pedrosa","year":"2022","unstructured":"Pedrosa DJ, Gandor F, Jost WH, Arlt C, Onuk K, Timmermann L. Characterization of advanced Parkinson\u2019s disease in Germany: results of the non-interventional OBSERVE-PD study. Neurol Res Pract. 2022;4(1):9.","journal-title":"Neurol Res Pract"},{"issue":"1","key":"4817_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12883-022-02554-z","volume":"22","author":"A Stefani","year":"2022","unstructured":"Stefani A, Tessitore A, Tambasco N, Cossu G, Ceravolo MG, Defazio G, et al. Criteria for identification of advanced Parkinson\u2019s disease: the results of the Italian subgroup of OBSERVE-PD observational study. BMC Neurol. 2022;22(1):41.","journal-title":"BMC Neurol"},{"key":"4817_CR22","first-page":"100075","volume":"4","author":"A Evans","year":"2021","unstructured":"Evans A, Fung VSC, O\u2019Sullivan JD, Stell R, White R, Williams DR, et al. Characteristics of advanced Parkinson\u2019s disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study. Clin Park Relat Disord. 2021;4:100075.","journal-title":"Clin Park Relat Disord"},{"key":"4817_CR23","first-page":"6635618","volume":"2021","author":"JA Szasz","year":"2021","unstructured":"Szasz JA, Jianu DC, Simu MA, Constantin VA, Dulamea AO, Onuk K, et al. Characterizing Advanced Parkinson\u2019s Disease: Romanian Subanalysis from the OBSERVE-PD Study. Park Dis. 2021;2021:6635618.","journal-title":"Park Dis"},{"key":"4817_CR24","doi-asserted-by":"crossref","unstructured":"Moes HR, Buskens E, van Laar T. Comment on Does the 5-2-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. June 2024;5(1):189.","DOI":"10.1186\/s12883-024-03692-2"},{"issue":"4","key":"4817_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5603\/pjnns.99624","volume":"58","author":"K Duda","year":"2024","unstructured":"Duda K, Chmiela T, Cie\u015bla-Fu\u0142awka A, Gawryluk J, Siuda J. Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson\u2019s Disease? Neurol Neurochir Pol. 2024;58(4):422\u20138.","journal-title":"Neurol Neurochir Pol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04817-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:30:22Z","timestamp":1778031022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04817-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4817"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04817-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Ethics Committee of the Faculty of Medicine and Pharmacy of Casablanca on October 26, 2023 (Approval number: 06\/2023), and authorization was granted by the regional directorate of the Ministry of Health on August 1, 2023 (Approval number: 5355). Written consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent for publication was obtained from all participants as part of the study consent process approved by the ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"303"}}